Sina Mozaffari-Jovin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sina Mozaffari-Jovin has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
- Markus Christian Wahl
Freie Universität Berlin, Institute of Chemistry and Biochemistry, Laboratory of Structural Biochemistry, Takustr. 6, 14195 Berlin, Germany
9 shared publications - Reinhard Lührmann
Emeritus Group Cellular Biochemistry, Max Planck Institute for Multidisciplinary Sciences, Am Fassberg 11, Göttingen, Germany
8 shared publications Reinhard Lührmann
Max Planck Institute for Multidisciplinary Sciences Göttingen Germany
6 shared publicationsHenning Urlaub
Max Planck Institute for Multidisciplinary Sciences Göttingen Germany
5 shared publications- Majlinda Lako
Biosciences Institute, Newcastle University, UK
5 shared publications - Colin A. Johnson
Division of Molecular Medicine, Leeds Institute of Medical Research, University of Leeds, Leeds, UK
4 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 10365
Cell-autonomous restoration of splicing homeostasis and RP11 phenotype in patient-derived RPE and retinal organoids by PRPF31.AAV gene therapy
Mutations in the PRPF31 gene cause retinitis pigmentosa type 11 (RP11), a progressive blinding disease triggered by defects in the spliceosome, the cellular machinery responsible for RNA processing. Although gene replacement holds therapeutic promise, it remains unclear whether it can effectively rescue both primary target cell types across different disease stages. Here we show that viral-mediated delivery of PRPF31 to patient-derived retinal pigment epithelium (RPE) cells and 3D retinal organoids restores RNA splicing activity and reverses core cellular pathology. Gene delivery cleared toxic protein aggregates, restored essential RPE functions, including structural polarity, cilia integrity, and cellular waste clearance, and boosted light-evoked activity in photoreceptors. Notably, robust rescue was achievable even in mature cells, whereas combining gene therapy with autophagy-activating drugs offered no added benefit. These findings demonstrate that restoring splicing homeostasis alone drives functional recovery, supporting a broad clinical window for PRPF31 gene therapy in RP11.
- 30 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 10365
Open AccessCell-autonomous restoration of splicing homeostasis and RP11 phenotype in patient-derived RPE and retinal organoids by PRPF31.AAV gene therapy
Mutations in the PRPF31 gene cause retinitis pigmentosa type 11 (RP11), a progressive blinding disease triggered by defects in the spliceosome, the cellular machinery responsible for RNA processing. Although gene replacement holds therapeutic promise, it remains unclear whether it can effectively rescue both primary target cell types across different disease stages. Here we show that viral-mediated delivery of PRPF31 to patient-derived retinal pigment epithelium (RPE) cells and 3D retinal organoids restores RNA splicing activity and reverses core cellular pathology. Gene delivery cleared toxic protein aggregates, restored essential RPE functions, including structural polarity, cilia integrity, and cellular waste clearance, and boosted light-evoked activity in photoreceptors. Notably, robust rescue was achievable even in mature cells, whereas combining gene therapy with autophagy-activating drugs offered no added benefit. These findings demonstrate that restoring splicing homeostasis alone drives functional recovery, supporting a broad clinical window for PRPF31 gene therapy in RP11.
- Open Access
- 19 May 2026
- Published by Springer Nature in Research Square
Cell-autonomous restoration of splicing homeostasis and RP11 phenotype in patient-derived RPE and retinal organoids by PRPF31.AAV gene therapy
Mutations in PRPF31 gene cause retinitis pigmentosa type 11 (RP11) through haploinsufficiency, impairing spliceosome assembly and triggering progressive retinal degeneration. While gene augmentation holds therapeutic promise, key questions remain regarding the mechanistic basis of rescue and its therapeutic efficacy across all primarily affected human retinal cell types and disease stages. Here, we utilised patient-specific induced pluripotent stem cells (iPSCs)-derived retinal pigment epithelium (RPE) cells and three-dimensional retinal organoids (ROs) to determine the therapeutic mechanism of AAV-mediated PRPF31 delivery. Using the ShH10(Y445F) serotype to ensure robust dual targeting of RPE and photoreceptors, we demonstrated that PRPF31 transduction restores nuclear localisation, reorganises SC35+ nuclear speckles and enhances p-SF3B1⁺ active spliceosome foci. Transcriptomic and proteomic profiling revealed a global rescue of splicing activity and upregulation of phagocytosis, protein aggregate clearance pathways, and mitochondrial proteins. These molecular shifts facilitated the clearance of proteotoxic cytoplasmic aggregates and reversed key functional deficits; specifically, they reinforced RPE apical-basal polarity, restored phagocytic capacity and normal ciliary morphology and incidence, and boosted light-evoked activity in photoreceptors. Combining gene therapy with rapamycin-mediated-autophagy activation conferred no additive benefit, identifying the restoration of splicing homeostasis as the critical therapeutic driver. Notably, substantial phenotypic rescue is achievable in mature RPE, supporting a broad clinical window for intervention. Collectively, these data provide a systems-level validation of ShH10(Y445F)-PRPF31 gene therapy and establish a mechanistic framework for its clinical translation in RP11.
- 19 May 2026
- Published by Springer Nature in Research Square
Open AccessCell-autonomous restoration of splicing homeostasis and RP11 phenotype in patient-derived RPE and retinal organoids by PRPF31.AAV gene therapy
Mutations in PRPF31 gene cause retinitis pigmentosa type 11 (RP11) through haploinsufficiency, impairing spliceosome assembly and triggering progressive retinal degeneration. While gene augmentation holds therapeutic promise, key questions remain regarding the mechanistic basis of rescue and its therapeutic efficacy across all primarily affected human retinal cell types and disease stages. Here, we utilised patient-specific induced pluripotent stem cells (iPSCs)-derived retinal pigment epithelium (RPE) cells and three-dimensional retinal organoids (ROs) to determine the therapeutic mechanism of AAV-mediated PRPF31 delivery. Using the ShH10(Y445F) serotype to ensure robust dual targeting of RPE and photoreceptors, we demonstrated that PRPF31 transduction restores nuclear localisation, reorganises SC35+ nuclear speckles and enhances p-SF3B1⁺ active spliceosome foci. Transcriptomic and proteomic profiling revealed a global rescue of splicing activity and upregulation of phagocytosis, protein aggregate clearance pathways, and mitochondrial proteins. These molecular shifts facilitated the clearance of proteotoxic cytoplasmic aggregates and reversed key functional deficits; specifically, they reinforced RPE apical-basal polarity, restored phagocytic capacity and normal ciliary morphology and incidence, and boosted light-evoked activity in photoreceptors. Combining gene therapy with rapamycin-mediated-autophagy activation conferred no additive benefit, identifying the restoration of splicing homeostasis as the critical therapeutic driver. Notably, substantial phenotypic rescue is achievable in mature RPE, supporting a broad clinical window for intervention. Collectively, these data provide a systems-level validation of ShH10(Y445F)-PRPF31 gene therapy and establish a mechanistic framework for its clinical translation in RP11.
- Open Access
- 2 July 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1-11
Performance of KRAS mutation detection in plasma exosomes from patients with early-stage colorectal cancer
Liquid biopsy is a minimally invasive method, which is an alternative to tissue biopsy in solid cancers to detect driver mutations, monitor treatment responses, and estimate prognosis. Exosomes are a group of extracellular vesicles that are detected in body fluids and are more stable than cell-free DNA and circulating tumor cells. Genetic data of parental cells can be packaged into exosomes, analysis of which could help determine the genetic modifications of cells before the emergence of disease symptoms. Here, we sought to investigate the KRAS mutation detection in exosomal DNA extracted from the plasma of patients with colorectal cancer. This study was conducted on 42 colorectal cancer patients with stage I-III. First, exosomes were purified from the plasma of patients using Size Exclusion Chromatography (SEC), and then DNA was extracted from the samples using the phenol-chloroform-isoamyl alcohol (PCI) method. Next, the presence of three KRAS variants was examined using the Intplex quantitative PCR method. The mutant allele frequency was measured with a sensitivity of 0.01%. About 85% of the tested exosomal DNA samples had one or two KRAS mutations. The measured mutant allele frequency had a median of 1.18% (with a range of 0.01–63.33%). Moreover, we evaluated the concordance of mutation detection between patient exosome and tumor tissue DNA samples. We concluded that the investigation of mutation in genetic contents of exosomes extracted from the plasma of cancer patients at early stages could be performed with high sensitivity and could accelerate determination of the best therapy process for patients.
- 2 July 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1-11
Open AccessPerformance of KRAS mutation detection in plasma exosomes from patients with early-stage colorectal cancer
Liquid biopsy is a minimally invasive method, which is an alternative to tissue biopsy in solid cancers to detect driver mutations, monitor treatment responses, and estimate prognosis. Exosomes are a group of extracellular vesicles that are detected in body fluids and are more stable than cell-free DNA and circulating tumor cells. Genetic data of parental cells can be packaged into exosomes, analysis of which could help determine the genetic modifications of cells before the emergence of disease symptoms. Here, we sought to investigate the KRAS mutation detection in exosomal DNA extracted from the plasma of patients with colorectal cancer. This study was conducted on 42 colorectal cancer patients with stage I-III. First, exosomes were purified from the plasma of patients using Size Exclusion Chromatography (SEC), and then DNA was extracted from the samples using the phenol-chloroform-isoamyl alcohol (PCI) method. Next, the presence of three KRAS variants was examined using the Intplex quantitative PCR method. The mutant allele frequency was measured with a sensitivity of 0.01%. About 85% of the tested exosomal DNA samples had one or two KRAS mutations. The measured mutant allele frequency had a median of 1.18% (with a range of 0.01–63.33%). Moreover, we evaluated the concordance of mutation detection between patient exosome and tumor tissue DNA samples. We concluded that the investigation of mutation in genetic contents of exosomes extracted from the plasma of cancer patients at early stages could be performed with high sensitivity and could accelerate determination of the best therapy process for patients.
- 24 February 2025
- Published by Wiley in Biotechnology Journal
- Vol. 20 (2) , e202400596
mRNA Vaccines: Design Principles, Mechanisms, and Manufacturing—Insights From COVID‐19 as a Model for Combating Infectious Diseases
The full approval of two SARS‐CoV‐2 mRNA vaccines, Comirnaty and Spikevax, has greatly accelerated the development of numerous mRNA vaccine candidates targeting infectious diseases and cancer. mRNA vaccines provide a rapid, safe, and versatile manufacturing process while eliciting strong humoral and cellular immune responses, making them particularly beneficial for addressing emerging pandemics. Recent advancements in modified nucleotides and lipid nanoparticle delivery systems have further emphasized the potential of this vaccine platform. Despite these transformative opportunities, significant improvements are needed to enhance vaccine efficacy, stability, and immunogenicity.This review outlines the fundamentals of mRNA vaccine design, the manufacturing process, and administration strategies, along with various optimization approaches. It also offers a comprehensive overview of the mRNA vaccine candidates developed since the onset of the COVID‐19 pandemic, the challenges posed by emerging SARS‐CoV‐2 variants, and current strategies to address these variants. Finally, we discuss the potential of broad‐spectrum and combined mRNA vaccines and examine the challenges and future prospects of the mRNA vaccine platform.
- 24 February 2025
- Published by Wiley in Biotechnology Journal
- Vol. 20 (2) , e202400596
mRNA Vaccines: Design Principles, Mechanisms, and Manufacturing—Insights From COVID‐19 as a Model for Combating Infectious Diseases
The full approval of two SARS‐CoV‐2 mRNA vaccines, Comirnaty and Spikevax, has greatly accelerated the development of numerous mRNA vaccine candidates targeting infectious diseases and cancer. mRNA vaccines provide a rapid, safe, and versatile manufacturing process while eliciting strong humoral and cellular immune responses, making them particularly beneficial for addressing emerging pandemics. Recent advancements in modified nucleotides and lipid nanoparticle delivery systems have further emphasized the potential of this vaccine platform. Despite these transformative opportunities, significant improvements are needed to enhance vaccine efficacy, stability, and immunogenicity.This review outlines the fundamentals of mRNA vaccine design, the manufacturing process, and administration strategies, along with various optimization approaches. It also offers a comprehensive overview of the mRNA vaccine candidates developed since the onset of the COVID‐19 pandemic, the challenges posed by emerging SARS‐CoV‐2 variants, and current strategies to address these variants. Finally, we discuss the potential of broad‐spectrum and combined mRNA vaccines and examine the challenges and future prospects of the mRNA vaccine platform.
- Open Access
- 11 April 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-17
PRPF8-mediated dysregulation of hBrr2 helicase disrupts human spliceosome kinetics and 5´-splice-site selection causing tissue-specific defects
The carboxy-terminus of the spliceosomal protein PRPF8, which regulates the RNA helicase Brr2, is a hotspot for mutations causing retinitis pigmentosa-type 13, with unclear role in human splicing and tissue-specificity mechanism. We used patient induced pluripotent stem cells-derived cells, carrying the heterozygous PRPF8 c.6926 A > C (p.H2309P) mutation to demonstrate retinal-specific endophenotypes comprising photoreceptor loss, apical-basal polarity and ciliary defects. Comprehensive molecular, transcriptomic, and proteomic analyses revealed a role of the PRPF8/Brr2 regulation in 5’-splice site (5’SS) selection by spliceosomes, for which disruption impaired alternative splicing and weak/suboptimal 5’SS selection, and enhanced cryptic splicing, predominantly in ciliary and retinal-specific transcripts. Altered splicing efficiency, nuclear speckles organisation, and PRPF8 interaction with U6 snRNA, caused accumulation of active spliceosomes and poly(A)+ mRNAs in unique splicing clusters located at the nuclear periphery of photoreceptors. Collectively these elucidate the role of PRPF8/Brr2 regulatory mechanisms in splicing and the molecular basis of retinal disease, informing therapeutic approaches.
- 11 April 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-17
Open AccessPRPF8-mediated dysregulation of hBrr2 helicase disrupts human spliceosome kinetics and 5´-splice-site selection causing tissue-specific defects
The carboxy-terminus of the spliceosomal protein PRPF8, which regulates the RNA helicase Brr2, is a hotspot for mutations causing retinitis pigmentosa-type 13, with unclear role in human splicing and tissue-specificity mechanism. We used patient induced pluripotent stem cells-derived cells, carrying the heterozygous PRPF8 c.6926 A > C (p.H2309P) mutation to demonstrate retinal-specific endophenotypes comprising photoreceptor loss, apical-basal polarity and ciliary defects. Comprehensive molecular, transcriptomic, and proteomic analyses revealed a role of the PRPF8/Brr2 regulation in 5’-splice site (5’SS) selection by spliceosomes, for which disruption impaired alternative splicing and weak/suboptimal 5’SS selection, and enhanced cryptic splicing, predominantly in ciliary and retinal-specific transcripts. Altered splicing efficiency, nuclear speckles organisation, and PRPF8 interaction with U6 snRNA, caused accumulation of active spliceosomes and poly(A)+ mRNAs in unique splicing clusters located at the nuclear periphery of photoreceptors. Collectively these elucidate the role of PRPF8/Brr2 regulatory mechanisms in splicing and the molecular basis of retinal disease, informing therapeutic approaches.
- 5 July 2023
- Published by Elsevier in Journal of Controlled Release
- Vol. 360, 316-334
Characterization of stability, safety and immunogenicity of the mRNA lipid nanoparticle vaccine Iribovax® against COVID-19 in nonhuman primates
- 5 July 2023
- Published by Elsevier in Journal of Controlled Release
- Vol. 360, 316-334
Characterization of stability, safety and immunogenicity of the mRNA lipid nanoparticle vaccine Iribovax® against COVID-19 in nonhuman primates
- Open Access
- 16 March 2022
- Published by Wiley in Clinical and Translational Medicine
- Vol. 12 (3) , e759
Activation of autophagy reverses progressive and deleterious protein aggregation in PRPF31 patient‐induced pluripotent stem cell‐derived retinal pigment epithelium cells
Introduction: Mutations in pre‐mRNA processing factor 31 (PRPF31), a core protein of the spliceosomal tri‐snRNP complex, cause autosomal‐dominant retinitis pigmentosa (adRP). It has remained an enigma why mutations in ubiquitously expressed tri‐snRNP proteins result in retina‐specific disorders, and so far, the underlying mechanism of splicing factors‐related RP is poorly understood.Methods: We used the induced pluripotent stem cell (iPSC) technology to generate retinal organoids and RPE models from four patients with severe and very severe PRPF31‐adRP, unaffected individuals and a CRISPR/Cas9 isogenic control.Results: To fully assess the impacts of PRPF31 mutations, quantitative proteomics analyses of retinal organoids and RPE cells were carried out showing RNA splicing, autophagy and lysosome, unfolded protein response (UPR) and visual cycle‐related pathways to be significantly affected. Strikingly, the patient‐derived RPE and retinal cells were characterised by the presence of large amounts of cytoplasmic aggregates containing the mutant PRPF31 and misfolded, ubiquitin‐conjugated proteins including key visual cycle and other RP‐linked tri‐snRNP proteins, which accumulated progressively with time. The mutant PRPF31 variant was not incorporated into splicing complexes, but reduction of PRPF31 wild‐type levels led to tri‐snRNP assembly defects in Cajal bodies of PRPF31 patient retinal cells, altered morphology of nuclear speckles and reduced formation of active spliceosomes giving rise to global splicing dysregulation. Moreover, the impaired waste disposal mechanisms further exacerbated aggregate formation, and targeting these by activating the autophagy pathway using Rapamycin reduced cytoplasmic aggregates, leading to improved cell survival.Conclusions: Our data demonstrate that it is the progressive aggregate accumulation that overburdens the waste disposal machinery rather than direct PRPF31‐initiated mis‐splicing, and thus relieving the RPE cells from insoluble cytoplasmic aggregates presents a novel therapeutic strategy that can be combined with gene therapy studies to fully restore RPE and retinal cell function in PRPF31‐adRP patients.
- 16 March 2022
- Published by Wiley in Clinical and Translational Medicine
- Vol. 12 (3) , e759
Open AccessActivation of autophagy reverses progressive and deleterious protein aggregation in PRPF31 patient‐induced pluripotent stem cell‐derived retinal pigment epithelium cells
Introduction: Mutations in pre‐mRNA processing factor 31 (PRPF31), a core protein of the spliceosomal tri‐snRNP complex, cause autosomal‐dominant retinitis pigmentosa (adRP). It has remained an enigma why mutations in ubiquitously expressed tri‐snRNP proteins result in retina‐specific disorders, and so far, the underlying mechanism of splicing factors‐related RP is poorly understood.Methods: We used the induced pluripotent stem cell (iPSC) technology to generate retinal organoids and RPE models from four patients with severe and very severe PRPF31‐adRP, unaffected individuals and a CRISPR/Cas9 isogenic control.Results: To fully assess the impacts of PRPF31 mutations, quantitative proteomics analyses of retinal organoids and RPE cells were carried out showing RNA splicing, autophagy and lysosome, unfolded protein response (UPR) and visual cycle‐related pathways to be significantly affected. Strikingly, the patient‐derived RPE and retinal cells were characterised by the presence of large amounts of cytoplasmic aggregates containing the mutant PRPF31 and misfolded, ubiquitin‐conjugated proteins including key visual cycle and other RP‐linked tri‐snRNP proteins, which accumulated progressively with time. The mutant PRPF31 variant was not incorporated into splicing complexes, but reduction of PRPF31 wild‐type levels led to tri‐snRNP assembly defects in Cajal bodies of PRPF31 patient retinal cells, altered morphology of nuclear speckles and reduced formation of active spliceosomes giving rise to global splicing dysregulation. Moreover, the impaired waste disposal mechanisms further exacerbated aggregate formation, and targeting these by activating the autophagy pathway using Rapamycin reduced cytoplasmic aggregates, leading to improved cell survival.Conclusions: Our data demonstrate that it is the progressive aggregate accumulation that overburdens the waste disposal machinery rather than direct PRPF31‐initiated mis‐splicing, and thus relieving the RPE cells from insoluble cytoplasmic aggregates presents a novel therapeutic strategy that can be combined with gene therapy studies to fully restore RPE and retinal cell function in PRPF31‐adRP patients.
- Top Cited PapersOpen Access
- 12 October 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-19
Disrupted alternative splicing for genes implicated in splicing and ciliogenesis causes PRPF31 retinitis pigmentosa
Mutations in pre-mRNA processing factors (PRPFs) cause autosomal-dominant retinitis pigmentosa (RP), but it is unclear why mutations in ubiquitously expressed genes cause non-syndromic retinal disease. Here, we generate transcriptome profiles from RP11 (PRPF31-mutated) patient-derived retinal organoids and retinal pigment epithelium (RPE), as well as Prpf31+/− mouse tissues, which revealed that disrupted alternative splicing occurred for specific splicing programmes. Mis-splicing of genes encoding pre-mRNA splicing proteins was limited to patient-specific retinal cells and Prpf31+/− mouse retinae and RPE. Mis-splicing of genes implicated in ciliogenesis and cellular adhesion was associated with severe RPE defects that include disrupted apical – basal polarity, reduced trans-epithelial resistance and phagocytic capacity, and decreased cilia length and incidence. Disrupted cilia morphology also occurred in patient-derived photoreceptors, associated with progressive degeneration and cellular stress. In situ gene editing of a pathogenic mutation rescued protein expression and key cellular phenotypes in RPE and photoreceptors, providing proof of concept for future therapeutic strategies.
- 12 October 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-19
Top Cited PapersOpen AccessDisrupted alternative splicing for genes implicated in splicing and ciliogenesis causes PRPF31 retinitis pigmentosa
Mutations in pre-mRNA processing factors (PRPFs) cause autosomal-dominant retinitis pigmentosa (RP), but it is unclear why mutations in ubiquitously expressed genes cause non-syndromic retinal disease. Here, we generate transcriptome profiles from RP11 (PRPF31-mutated) patient-derived retinal organoids and retinal pigment epithelium (RPE), as well as Prpf31+/− mouse tissues, which revealed that disrupted alternative splicing occurred for specific splicing programmes. Mis-splicing of genes encoding pre-mRNA splicing proteins was limited to patient-specific retinal cells and Prpf31+/− mouse retinae and RPE. Mis-splicing of genes implicated in ciliogenesis and cellular adhesion was associated with severe RPE defects that include disrupted apical – basal polarity, reduced trans-epithelial resistance and phagocytic capacity, and decreased cilia length and incidence. Disrupted cilia morphology also occurred in patient-derived photoreceptors, associated with progressive degeneration and cellular stress. In situ gene editing of a pathogenic mutation rescued protein expression and key cellular phenotypes in RPE and photoreceptors, providing proof of concept for future therapeutic strategies.
- 1 March 2018
- Published by Elsevier in Molecular Cell
- Vol. 69 (6) , 979-992.e6
Prp19/Pso4 Is an Autoinhibited Ubiquitin Ligase Activated by Stepwise Assembly of Three Splicing Factors
- 1 March 2018
- Published by Elsevier in Molecular Cell
- Vol. 69 (6) , 979-992.e6
Prp19/Pso4 Is an Autoinhibited Ubiquitin Ligase Activated by Stepwise Assembly of Three Splicing Factors